Journal Cover Translational Surgery
  [0 followers]  Follow
    
  This is an Open Access Journal Open Access journal
   ISSN (Print) 2468-5585 - ISSN (Online) 2455-9598
   Published by Medknow Publishers Homepage  [356 journals]
  • Specificity and potency of curcumin derivative 64PH in inhibiting HepG2
           human hepatocellular carcinoma cell proliferation

    • Authors: Xueqian Li, Qiaowei Zheng, Yingchen Zhuo, Jingguo Chen, Wenbin Ma, Xue Zhao, Peipei Zhao, Xuanlin Liu, Haimin Lei, Junwang Xu, Weiyi Feng
      Pages: 1 - 5
      Abstract: Xueqian Li, Qiaowei Zheng, Yingchen Zhuo, Jingguo Chen, Wenbin Ma, Xue Zhao, Peipei Zhao, Xuanlin Liu, Haimin Lei, Junwang Xu, Weiyi Feng
      Translational Surgery 2017 2(1):1-5
      Aim: This study aimed to investigate the specificity and potency of curcumin derivative 64PH in inhibiting the proliferation of HepG2 human hepatoma cells in vitro. Methods: Various concentrations of 64PH were administrated to HepG2 hepatoma cells and HL7702 hepatic cells. The viability of cells was evaluated by methyl thiazolyl tetrazolium assay. The concentration-inhibition rates in the two cell lines were calculated, and the accumulation normal distribution function was adopted to fit their rate curves. The differences of the rates between the two cells were observed on the 3rd day of 64PH treatment. The maximum difference and the 95% credibility interval of the corresponding 64PH concentration were evaluated. Results: 64PH inhibited the proliferation of HepG2 and HL7702 cells in vitro. To fit the concentration-effect curves on the 3rd day, the determination coefficients (γ2) were more than 0.99, the half maximal inhibitory concentration (IC50) was 3.07 and 4.28 μg/mL of 64PH, respectively, and their ratio was 1.39. To fit the normal distribution function of the differences of concentration-inhibition rates between HepG2 and HL7702 cells (s2 = 0.9861), the maximum difference of inhibition rates was 33.58%, and the corresponding concentration of 64PH and the 95% credibility interval were 2.65 and 3.52 μg/mL, respectively. Conclusion: In vitro, HepG2 cells are more sensitive than HL7702 cells due to the presence of 64PH. The inhibition of cell proliferation induced by 64PH is stronger in HepG2 than in HL7702 at concentrations between 2.65 and 3.52 μg/mL. 64PH has the potential to be a therapeutic approach in hepatocellular carcinoma and to achieve the desired efficacy and safety.
      Citation: Translational Surgery 2017 2(1):1-5
      PubDate: Tue,21 Mar 2017
      DOI: 10.4103/ts.ts_38_16
      Issue No: Vol. 2, No. 1 (2017)
       
  • Application value of endobronchial ultrasound-guided transbronchial needle
           aspiration in the diagnosis and treatment of mediastinal and pulmonary
           diseases

    • Authors: Wenkui Sun, Qian Qian, Xinwu Xiao, Yong Song
      Pages: 6 - 9
      Abstract: Wenkui Sun, Qian Qian, Xinwu Xiao, Yong Song
      Translational Surgery 2017 2(1):6-9
      Aim: This study aims to investigate the value of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) in the diagnosis and treatment of mediastinal and pulmonary diseases. Methods: The clinical data of 52 patients who were hospitalized in the Department of Respiratory and Critical Care Medicine at Jinling Hospital from July 2014 to February 2015 with documented EBUS-TBNA was obtained. Results: Positive results of EBUS-TBNA biopsy were statistically compared to the final diagnosis. A total of 82 specimens from 52 patients were obtained through EBUS-TBNA biopsy. Out of 52, 45 patients had concurrent surgical pathology, including 33 malignant lesions and 12 benign lesions. There were 7 patients with false-negative results, including 1 case of pulmonary sclerosing hemangioma, 4 cases of lung cancer, and 2 cases of tuberculosis. The sensitivity of EBUS-TBNA in this study was 85.2%, accuracy of 85.4%, positive predictive value of 100%, and negative predictive value of 7.7%. There were no serious complications. Conclusion: EBUS-TBNA is a safe and minimally invasive method for the diagnosis of mediastinal and pulmonary diseases. It may also have utility as a therapeutic option during the diagnostic process of some diseases.
      Citation: Translational Surgery 2017 2(1):6-9
      PubDate: Tue,21 Mar 2017
      DOI: 10.4103/ts.ts_34_16
      Issue No: Vol. 2, No. 1 (2017)
       
  • The cross-contaminated cell lines of adenoid cystic carcinoma: A crucial
           concern

    • Authors: Nan-Nan Liu, Sen-Lin Zhang, Wei Chen
      Pages: 10 - 13
      Abstract: Nan-Nan Liu, Sen-Lin Zhang, Wei Chen
      Translational Surgery 2017 2(1):10-13
      Adenoid cystic carcinoma (ACC) is a common type of salivary gland cancer, characterized by slow growth but high incidence of distant metastasis. Distant metastasis occurs in 25%–50% of ACC patients and more commonly in lungs. However, the molecular mechanism underlying the aggressive growth of ACC remains obscure. Human tumor cell lines are extremely useful in studying cancer biology, under both in vitro and in vivo condition. Unfortunately, the tumor cell lines are susceptible to cross-contamination, by other cell lines, during routine culture. Recent studies have proved that most of the ACC cell lines, established for preclinical research, are either cross-contaminated or nonhuman cells. Here, we review the literature assessing the identity of ACC cell lines, dated up to September 1, 2016, using PubMed, EMBASE, and the China National Knowledge Infrastructure databases with the following keywords: “adenoid cystic carcinoma,” “cell line,” and “characterization” or “contamination.” According to the results, only salivary adenoid cystic carcinoma (SACC)-83/SACC-lung metastasis, the HPV-transformed ACC-112 and the two newly established moderately differentiated adenocarcinoma-ACC-01 and LACC-1 cell lines are authentic ACC cell lines. These results suggest that, in the future, it is crucial to authenticate the ACC cell lines before research.
      Citation: Translational Surgery 2017 2(1):10-13
      PubDate: Tue,21 Mar 2017
      DOI: 10.4103/2468-5585.200513
      Issue No: Vol. 2, No. 1 (2017)
       
  • Advances in multi-therapies for the treatment of Ewing's
           sarcoma

    • Authors: Lei Zhang, Xing Zhou, Xiaozhou Liu, Chengjun Li, Sujia Wu
      Pages: 14 - 18
      Abstract: Lei Zhang, Xing Zhou, Xiaozhou Liu, Chengjun Li, Sujia Wu
      Translational Surgery 2017 2(1):14-18
      Ewing's sarcoma (ES) is a type of bone and soft tissue tumor that is highly invasive and primarily occurs in children and adolescents. In recent years, with the combination chemotherapy, surgery, and radiotherapy, prognosis, and quality of life have significantly improved. The overall survival (OS) rate is 65%–75%. However, metastasis and recurrence after surgical resection are still the main determinants of mortality. The OS rate in these patients is <30%. Exploring the pathogenesis of ES and looking for effective targeted therapies are the primary focus of many research teams. A global effort to improve the clinical efficacy of chemotherapy while reducing the toxic side effects, has led to further advances. We summarize the current multidisciplinary treatment advances in ES, with an emphasis on molecular targeted therapy and immunotherapy.
      Citation: Translational Surgery 2017 2(1):14-18
      PubDate: Tue,21 Mar 2017
      DOI: 10.4103/ts.ts_32_16
      Issue No: Vol. 2, No. 1 (2017)
       
  • A case of surgical enucleation of a giant esophageal leiomyoma

    • Authors: Shaohua Zhou, Shanshan Li, Nannan Guo, Wen Zhang
      Pages: 19 - 21
      Abstract: Shaohua Zhou, Shanshan Li, Nannan Guo, Wen Zhang
      Translational Surgery 2017 2(1):19-21
      Esophageal leiomyoma is the most common benign esophageal tumor. When dealing with a giant esophageal tumor, tumor resection, and esophagogastric anastomosis are normally adopted by clinicians. However, postoperatively, patients always experience a poor quality of life because of the destruction of the normal anatomy. We present a case of resection of an esophageal leiomyoma with the integrity of esophagus maintained.
      Citation: Translational Surgery 2017 2(1):19-21
      PubDate: Tue,21 Mar 2017
      DOI: 10.4103/ts.ts_28_16
      Issue No: Vol. 2, No. 1 (2017)
       
  • Preoperative neoadjuvant gefitinib used in the treatment of a nonsmall
           cell lung cancer patient

    • Authors: Weihui Zheng, Weimin Mao
      Pages: 22 - 24
      Abstract: Weihui Zheng, Weimin Mao
      Translational Surgery 2017 2(1):22-24
      The epidermal growth factor receptor tyrosine kinase inhibitor (TKI) has been mainly applied in the second- and third-line treatment of advanced nonsmall cell lung cancer (NSCLC), but it is rarely used as a neoadjuvant therapy. This article aims to summarize and analyze a relevant case so as to provide some clinical experience for targeted neoadjuvant treatment modalities. A patient with NSCLC received the TKI gefitinib for preoperative neoadjuvant targeted therapy. A 76-year-old female who was given gefitinib for the neoadjuvant treatment was analyzed. The patients' general condition and also gender, age, smoking history, and efficacy of the targeted therapy and associated surgical experience were recorded. After the neoadjuvant treatment, the tumor shrinkage was obvious. At surgery, the surface vascular expansion on the tumor was observed. There was no increase in postoperative complications. The surgical pathology was adenocarcinoma of the lung associated with bronchioloalveolar carcinoma. Neoadjuvant targeted therapy could be a useful clinical treatment in NSCLC.
      Citation: Translational Surgery 2017 2(1):22-24
      PubDate: Tue,21 Mar 2017
      DOI: 10.4103/ts.ts_33_16
      Issue No: Vol. 2, No. 1 (2017)
       
 
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
 
Home (Search)
Subjects A-Z
Publishers A-Z
Customise
APIs
Your IP address: 54.146.5.196
 
About JournalTOCs
API
Help
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-2016